GLPwatch
Papers (9189)
Page 112 of 154, ranked by citation count.
- [A new era for glucagon-like peptide-1 receptor agonists].
- Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Cataract Development.
- Antidiabetic Effect of Abextide, a Long-Acting Exendin-4 Analogue in Cynomolgus Monkeys.
- GLP-1R activation restores Gas6-driven efferocytosis in senescent foamy macrophages to promote neural repair.
- [Effect of exendin-4 on lipid deposition in skeletal muscle of diet-induced obese mice and its underlying mechanism].
- Comparative Efficacy of Endoscopic Sleeve Gastroplasty (Esg) Versus Liraglutide in Weight Loss and Remission Of Obesity-Related Comorbidities: Twelve Months Follow-Up Results.
- Liraglutide attenuates autoimmune myocarditis by inhibiting NLRP3 and NF-κb pathways.
- Semaglutide and health risk: Development and validation of a LC-HRMS method for testing semaglutide in whole blood and application to real cases.
- Noninvasive quantitative evaluation of viable islet grafts using <sup>111</sup> In-exendin-4 SPECT/CT.
- Efficacy and safety of once-weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT-2 trial.
- Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes.
- Tirzepatide Induces Ferroptosis in Glioblastoma Cell Lines via the SOX2/SLC7A11 Axis: A Potential Therapeutic Strategy for Glioma Treatment.
- Dulaglutide reduces oxidative DNA damage and hypermethylation in the somatic cells of mice fed a high-energy diet by restoring redox balance, inflammatory responses, and DNA repair gene expressions.
- The GLP-1 Receptor Agonist Dulaglutide Attenuates Hepatic Steatosis in Obesity via a Weight-Independent Mechanism.
- The administration of Exendin-4 and CCK affects food intake differentially in female and male rats tested on an alternate day fasting paradigm.
- Liraglutide for Adolescents with Obesity. Reply.
- Comparative study on anorexigenic effect of glucagon-like peptide-1 receptor agonists in rats.
- Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.
- Exendin-4 attenuates inflammation-mediated endothelial cell apoptosis in varicose veins through inhibiting the MAPK-JNK signaling pathway.
- Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).
- Adropin/Tirzepatide Combination Mitigates Cardiac Metabolic Aberrations in a Rat Model of Polycystic Ovarian Syndrome, Implicating the Role of the AKT/GSK3β/NF-κB/NLRP3 Pathway.
- Clinical pearls for initiating and utilizing liraglutide in patients with type 2 diabetes.
- Liraglutide for adults living with obesity.
- Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet-induced Mouse Model.
- Applying the Social-Ecological Approach to Evaluate Diabetes Medication Management in Older People.
- Effectiveness of Low Doses of Semaglutide on Weight Loss and Body Composition Among Women in Their Menopause.
- Exendin-4 alleviates diabetic retinopathy by activating autophagy via regulation of the adenosine monophosphate-activated protein kinase/sirtuin 1 pathway.
- Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial.
- Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide.
- Sustained metabolic benefits of ΔTRTX-Ac1, a tarantula venom-derived peptide, when administered together with exenatide in high-fat fed mice.
- Liraglutide attenuates clozapine-induced mitochondrial dysfunction and improves energy metabolism in the brain of rats.
- Safety and effectiveness of dulaglutide in Chinese adults with type 2 diabetes mellitus in a real-world setting: A prospective, observational post-marketing study.
- Adverse effects with tirzepatide: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis.
- Exendin-4, a GLP-1 receptor agonist, suppresses diabetic retinopathy <i>in vivo</i> and <i>in vitro</i>.
- Preoperative Glucagon-Like Peptide-1 Receptor Agonists and Bariatric Surgery Outcomes: A Systematic Review.
- Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease.
- Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus.
- Peptide mapping analysis of synthetic semaglutide and liraglutide for generic development of drugs originating from recombinant DNA technology.
- Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review.
- Dopamine signalling in pancreatic islet cells and role in adaptations to metabolic stress.
- The effects of semaglutide, empagliflozin and their combination on the kidney sodium signal from magnetic resonance imaging: A prespecified, secondary analysis from a randomized, clinical trial.
- Non-Arteritic Anterior Ischemic Optic Neuropathy in an Otherwise Healthy Young Adult Patient Treated with Liraglutide and Semaglutide for Weight Loss: A Cautionary Tale.
- The Efficacy of Semaglutide on Hypothalamic Obesity Caused by Craniopharyngioma Surgery.
- Effect of liraglutide on microcirculation in rat model with absolute insulin deficiency.
- GLP-1 receptor agonists in obesity treatment: Effects on cardiometabolic variables and cardiovascular disease.
- Advances in Drug Treatments for Companion Animal Obesity.
- Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes.
- Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice.
- REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide.
- Impact of semaglutide and dulaglutide shortages on Pharmaceutical Benefits Scheme prescriptions supplied for type 2 diabetes treatment.
- Effect of acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, and estrus phase on cue- and drug-induced fentanyl seeking in female rats.
- Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
- Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease.
- GLP-1 receptor agonism and GIP receptor antagonism induce substantial alterations in enteroendocrine and islet cell populations in obese high fat fed mice.
- Supramolecular prodrug of SN38 based on endogenous albumin and SN38 prodrug modified with semaglutide side chain to improve the tumor distribution.
- Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.
- Long-lasting Glucagon-like Peptide 1 Analogue Exendin-4 Ameliorates the Secretory and Synthetic Function of Islets Isolated From Severely Scalded Rats.
- Liraglutide treatment and acylcarnitine profiles in Egyptian obese insulin-resistant females.
- Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series.
- Pharmacotherapy for obstructive sleep apnea: a critical review of randomized placebo-controlled trials.